Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern
Andrei E. Siniavin, Михаил С. Новиков, Vladimir А. Gushchin, Alexander A. Terechov, Igor A. Ivanov, Maria P. Paramonova, E. S. Gureeva, Л. И. Руссу, Nadezhda A. Kuznetsova, Elena V. Shidlovskaya, S. I. Luyksaar, Daria V. Vasina, Sergey A. Zolotov, Nailya А. Zigangirova, Denis Y. Logunov, Gintsburg Al
Abstract
Despite the widespread use of the COVID-19 vaccines, the search for effective antiviral drugs for the treatment of patients infected with SARS-CoV-2 is still relevant. Genetic variability leads to the continued circulation of new variants of concern (VOC). There is a significant decrease in the effectiveness of antibody-based therapy, which raises concerns about the development of new antiviral drugs with a high spectrum of activity against VOCs. We synthesized new analogs of uracil derivatives where uracil was substituted at the N1 and N3 positions. Antiviral activity was studied in Vero E6 cells against VOC, including currently widely circulating SARS-CoV-2 Omicron. All synthesized compounds of the panel showed a wide antiviral effect. In addition, we determined that these compounds inhibit the activity of recombinant SARS-CoV-2 RdRp. Our study suggests that these non-nucleoside uracil-based analogs may be of future use as a treatment for patients infected with circulating SARS-CoV-2 variants.